Sanofi Has Agreed To Acquire Provention Bio For $25.00/Share In Cash, Representing An Equity Value Of Approximately $2.9B

https://www.sanofi.com/en/media-room/press-releases/2023/2023-03-13-06-00-00-2625367

byBenzinga Newsdesk

March 13, 2023

1 minute read

https://www.sanofi.com/en/media-room/press-releases/2023/2023-03-13-06-00-00-2625367

RBC Capital Upgrades Gold Fields to Outperform, Raises Price Target to $11

By Benzinga Newsdesk

Today, 11:28 PM

RBC Capital analyst Josh Wolfson upgrades Gold Fields (NYSE:GFI) from Sector Perform to Outperform and raises the price target from $10.5 to $11.

GFI

Bitcoin, Ethereum, Dogecoin Fall: Will Strong Dollar Pin Down Crypto For A Year Or More?

By Shivdeep Dhaliwal

Today, 11:28 PM

Bitcoin and Ethereum were under pressure on Tuesday evening as the global cryptocurrency market cap fell 1% to $904.9 billion.

$DOGE

Cronos Down More Than 3% Within 24 hours

By Benzinga Insights

Today, 11:28 PM

Cronos's (CRYPTO: CRO) price has decreased 3.65% over the past 24 hours to $0.11, continuing its downward trend over the past week of -4.0%, moving from $0.11 to its current price.

$CRO

CORRECTION: BMO Capital Initiates Coverage On Avalara with Outperform Rating, Announces Price Target of $130 – Posted as AlloVir (NASDAQ: ALVR) on February 1, 2022

By Benzinga Newsdesk

Today, 11:28 PM

CORRECTION: BMO Capital analyst Daniel Jester initiates coverage on Avalara (NYSE:AVLR) with a Outperform rating and announces Price Target of $130. BMO has not initiated coverage of AlloVir (NASDAQ:ALVR). They

ALVR

Sanofi Has Agreed To Acquire Provention Bio For $25.00/Share In Cash, Representing An Equity Value Of Approximately $2.9B

Related Posts

RBC Capital Upgrades Gold Fields to Outperform, Raises Price Target to $11

Bitcoin, Ethereum, Dogecoin Fall: Will Strong Dollar Pin Down Crypto For A Year Or More?

Cronos Down More Than 3% Within 24 hours

CORRECTION: BMO Capital Initiates Coverage On Avalara with Outperform Rating, Announces Price Target of $130 – Posted as AlloVir (NASDAQ: ALVR) on February 1, 2022